Načítá se...
Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
Upadacitinib is a novel selective Janus kinase 1 inhibitor developed for treatment of rheumatoid arthritis and other autoimmune diseases. The objective of this study was to assess the pharmacokinetics and safety of a single upadacitinib dose in subjects with normal renal function and in subjects wit...
Uloženo v:
| Vydáno v: | J Clin Pharmacol |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6590375/ https://ncbi.nlm.nih.gov/pubmed/30633369 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1375 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|